The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors

Diseases of the Colon and Rectum

Volumn 52, Issue 2, 2009, Pages 319-326

  Hu, Tsung Hui ^a   Lin, Jui Wei ^a   Chen, Hong Hwa ^a   Liu, Li Feng ^b   Chuah, Seng Kee ^c   Tai, Ming Hong ^c,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Colon and rectum; Gastrointestinal stromal tumors; Hepatoma derived growth factor; Ki 67; Prognosis; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; HEPATOMA DERIVED GROWTH FACTOR; IMATINIB; KI 67 ANTIGEN; HEPATOMA-DERIVED GROWTH FACTOR; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; CELL NUCLEUS; COLORECTAL SURGERY; COLORECTAL TUMOR; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION; CHEMISTRY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 64049095088     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e31819d1666     Document Type: Article

References (37)

1. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82Y7.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577Y80.
3. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995;103: 41Y7.
4. Appelman HD. Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know. Am J Surg Pathol 1986;10(Suppl 1):83Y99.
5. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459Y65.
6. Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003;43:118Y26.
7. Carrillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997; 28:160Y5.
8. Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994;269:25143Y9.
9. Nakamura H, Kambe H, Egawa T, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989;183:273Y84.
10. Everett AD. Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev Dyn 2001;222:450Y8.
11. Enomoto H, Yoshida K, Kishima Y, et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002;36: 1519Y27.
12. Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000;105:567Y75.
13. Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest 1998;102:1208Y19.
14. Hu TH, Huang CC, Liu LF, et al. Expression of hepatomaderived growth factor in hepatocellular carcinoma. Cancer 2003;98:1444Y56.
15. Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep 2005;13:1075Y80.
16. Bernard K, Litman E, Fitzpatrick JL, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003;63:6716Y25.
17. Chang KC, Tai MH, Lin JW, et al. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 2007;121:1059Y65.
18. Changchien CR, Wu MC, Tasi WS, et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum 2004;47:1922Y9.
19. Hassan I, You YN, Dozois EJ, et al. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 2006; 49:609Y15.
20. Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004;30:1098Y103.
21. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9: 3329Y37.
22. Fletcher CD. Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol 2002;33:455.
23. Chiu YC, Lin JW, Changchien CS, et al. Clinicopathological characteristics and prognosis of patients with small intestinal stromal tumors. J Formos Med Assoc 2005;104:905Y12.
24. Hu TH, Lin JW, Changchien CS, Liu SY, Chiou SS, Chuang JH. Immunohistochemical analyses of gastric stromal tumors in Taiwanese. J Formos Med Assoc 2003;102:707Y14.
25. Abraham NG, Scapagnini G, Kappas A. Human heme oxygenase: cell cycle-dependent expression and DNA microarray identification of multiple gene responses after transduction of endothelial cells. J Cell Biochem 2003;90:1098Y111.
26. Miettinen M, Lasota J. Gastrointestinal stromal tumorsYdefinition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1Y12.
27. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134Y42.
28. Narron JV, Stoops TD, Barringhaus K, Matsumura M, Everett AD. Hepatoma-derived growth factor is expressed after vascular injury in the rat and stimulates smooth muscle cell migration. Pediatr Res 2006;59:778Y83.
29. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 2004;286:L1194Y201.
30. Okuda Y, Nakamura H, Yoshida K, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 2003;94:1034Y41.
31. Guo RP, Zhong C, Shi M, et al. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:547Y55.
32. Abouzied MM, Baader SL, Dietz F, Kappler J, Gieselmann V, Franken S. Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J 2004;378:169Y76.
33. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 2006;12:117Y22.
34. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987;326:515Y7.
35. Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285Y94.
36. Toquet C, Le Neel JC, Guillou L, et al. Elevated (9 or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases. Dig Dis Sci 2002;47:2247Y53.
37. Abouzied MM, El-Tahir HM, Prenner L, Haberlein H, Gieselmann V, Franken S. Hepatoma-derived growth factor. Significance of amino acid residues 81-100 in cell surface interaction and proliferative activity. J Biol Chem 2005;280:10945Y54.